Provided by Tiger Trade Technology Pte. Ltd.

Tenaya Therapeutics Inc

0.8524
-0.0405-4.54%
Post-market: 0.85830.0059+0.69%19:42 EDT
Volume:3.28M
Turnover:2.79M
Market Cap:184.55M
PE:-1.18
High:0.9000
Open:0.8929
Low:0.8240
Close:0.8929
52wk High:2.35
52wk Low:0.3600
Shares:216.51M
Float Shares:205.84M
Volume Ratio:0.37
T/O Rate:1.59%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7209
EPS(LYR):-1.3101
ROE:-83.84%
ROA:-43.72%
PB:1.50
PE(LYR):-0.65

Loading ...

Tenaya Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
Mar 12

Tenaya Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 12

Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027

Reuters
·
Mar 12

Tenaya Therapeutics reports Q4 EPS (12c), consensus (12c)

TIPRANKS
·
Mar 12

Tenaya Therapeutics Q4 EPS $(0.12) Beats $(0.13) Estimate

Benzinga
·
Mar 12

BRIEF-Tenaya Therapeutics Q4 Net Income USD -20.175 Million Vs. IBES Estimate USD -22 Million

Reuters
·
Mar 12

Tenaya Therapeutics Q4 Operating Expenses USD 20.775 Million

THOMSON REUTERS
·
Mar 12

Press Release: Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Dow Jones
·
Mar 12

Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301’s Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy

GlobeNewswire
·
Mar 09

Tenaya Therapeutics: Alnylam Partnership Validates Cardiovascular Platform and Supports Long-Term Buy Thesis

TIPRANKS
·
Mar 06

Tenaya Therapeutics: Alnylam Collaboration De-Risks Platform and Expands Cardiovascular Upside, Supporting Buy Rating

TIPRANKS
·
Mar 06

Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments

Reuters
·
Mar 05

Tenaya Therapeutics Announces Major Cardiovascular Gene Target Collaboration

TIPRANKS
·
Mar 05

BRIEF-Tenaya Therapeutics Enters Into Research Collaboration With Alnylam Pharmaceuticals To Identify And Validate Novel Genetic Targets For Cardiovascular Disease Therapeutics

Reuters
·
Mar 05

Tenaya Therapeutics Inc - Co to Validate up to 15 Gene Targets Under Agreement

THOMSON REUTERS
·
Mar 05

Tenaya Therapeutics Enters Into Research Collaboration With Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics

THOMSON REUTERS
·
Mar 05

Tenaya Therapeutics Inc - to Receive up to $10 Mln Upfront and up to $1.13 Bln in Milestone Payments

THOMSON REUTERS
·
Mar 05

Tenaya Therapeutics to Join Leerink Partners Global Healthcare Conference in Miami

Reuters
·
Mar 03

e.l.f., Crown Castle, DoorDash, Stag, Tenaya Shake-Up

TIPRANKS
·
Feb 28

Tenaya Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview

Reuters
·
Feb 28